28047-15-6 | Phenylac-Gln-OH

Packsize	Purity	Availability	Price	Discounted Price
1g	96%	in stock	$29.00	$20.00
5g	96%	in stock	$48.00	$34.00
25g	95%	in stock	$215.00	$150.00
100g	98%	in stock	$760.00	$532.00

Description

• Catalog Number: AF32351
• Chemical Name: Phenylac-Gln-OH
• CAS Number: 28047-15-6
• Molecular Formula: C13H16N2O4
• Molecular Weight: 264.2771
• MDL Number: MFCD01725188
• SMILES: O=C(Cc1ccccc1)N[C@H](C(=O)O)CCC(=O)N

Computed Properties

• Complexity: 338
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 19
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7

Literature

• Insights into myalgic encephalomyelitis/chronic fatigue syndrome phenotypes through comprehensive metabolomics.

  Scientific reports 20180101

• Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.

  Molecular genetics and metabolism 20121101

• Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.

  Journal of hepatology 20120101

• Structured approach to treat patients with acute liver failure: A hepatic emergency.

  Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine 20120101

• Effect of dietary nitrogen content on the urine metabolite profile of dairy cows assessed by nuclear magnetic resonance (NMR)-based metabolomics.

  Journal of agricultural and food chemistry 20111214

• Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer.

  PloS one 20110101

• Management of hepatic encephalopathy.

  International journal of hepatology 20110101

• Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study.

  Journal of proteome research 20101203

• An unfolded protein response is the initial cellular response to the expression of mutant matrilin-3 in a mouse model of multiple epiphyseal dysplasia.

  Cell stress & chaperones 20101101

• Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.

  Molecular genetics and metabolism 20100701

• Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.

  Hepatology (Baltimore, Md.) 20100601

• From interstitial cystitis to chronic pelvic pain.

  Journal of medicine and life 20100515

• Contribution of proteolytic and metabolic sources to hepatic glutamine by (2)H NMR analysis of urinary phenylacetylglutamine (2)H-enrichment from (2)H(2)O.

  Metabolic engineering 20100101

• New insights in nutritional management and amino acid supplementation in urea cycle disorders.

  Molecular genetics and metabolism 20100101

• A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091115

• L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats.

  Hepatology (Baltimore, Md.) 20090701

• L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.

  Hepatology (Baltimore, Md.) 20090701

• Acute fatal presentation of ornithine transcarbamylase deficiency in a previously healthy male.

  Hepatology international 20080901

• Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias.

  Current medicinal chemistry 20080601

• Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors.

  Investigational new drugs 20070401

• Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines.

  Molecular genetics and metabolism 20070101

• L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.

  Medical hypotheses 20070101

• Does acute glutamine depletion enhance the response of glutamine synthesis to fasting in muscle in adult and old rats?

  Clinical nutrition (Edinburgh, Scotland) 20050601

• Aging: gene silencing or gene activation?

  Medical hypotheses 20050101

• Pharmacokinetics of sodium phenylacetate and sodium benzoate following intravenous administration as both a bolus and continuous infusion to healthy adult volunteers.

  Molecular genetics and metabolism 20040401

• Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.

  Cancer chemotherapy and pharmacology 20031101

• A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report.

  Investigational new drugs 20031101

• Low water-soluble uremic toxins.

  Advances in renal replacement therapy 20031001

• Integration of [U-13C]glucose and 2H2O for quantification of hepatic glucose production and gluconeogenesis.

  NMR in biomedicine 20030601

• The preventive effect of antineoplaston AS2-1 on HCC recurrence.

  Oncology reports 20030101

• Glutamine transport in isolated epithelial intestinal cells. Identification of a Na+-dependent transport mechanism, highly specific for glutamine.

  Pflugers Archiv : European journal of physiology 20021201

• Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans.

  Journal of mass spectrometry : JMS 20020601

• An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans.

  American journal of physiology. Endocrinology and metabolism 20011001

• A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

• A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010801